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Abstract
Multiple P2 receptor-mediated mechanisms exist by which ATP can alter nociceptive sensitivity following tissue injury. Evidence from a variety of experimental strategies including genetic disruption studies and the development of selective antagonists has indicated that the activation of P2X receptor subytpes, including P2X 3 , P2X 2/3 , P2X 4 and P2X 7 , and P2Y (e.g. P2Y 2 ) receptors can modulate pain. For example, administration of a selective P2X 3 antagonist, A-317491, has been shown to effectively block both hyperalgesia and allodynia in different animal models of pathological pain.
Intrathecally delivered antisense oligonucleotides targeting P2X 4 receptors decrease tactile allodynia following nerve injury. Selective antagonists for the P2X 7 receptor also reduce sensitization in animal models of inflammatory and neuropathic pain providing evidence that purinergic glial-neural interactions are important modulators of noxious sensory neurotransmission. Additionally, activation of P2Y 2 receptors leads to sensitization of polymodal TRPV1 receptors. Thus, ATP acting at multiple purinergic receptors, either directly on neurons (e.g. P2X 3 , P2X 2/3 and P2Y receptors) or indirectly through neural-gial cell interactions (P2X 4 and P2X 7 receptors), alters nociceptive sensitivity. The development of selective antagonists for some of these P2 receptors has greatly aided investigations into the nociceptive role of ATP. This perspective highlights some of the recent advances to identify selective P2 receptor ligands, which has enhanced the investigation of ATP-related modulation of pain sensitivity.
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Introduction
Pain is a multidimensional sensory process that, acutely, is physiologically adaptive in response to dangerous (e.g. sharp, hot, or chemical stimuli) stimuli in the environment. Persistent pain can range from increased sensitivity to mildly painful stimuli (hyperalgesia) or to otherwise innocuous stimuli (allodynia) (Honore and Jarvis, 2006a) . It is well appreciated that distinct sensory mechanisms contribute to physiological pain, to pain arising from tissue damage (inflammatory or nociceptive pain) and to pain arising from injury to the nervous system (neuropathic pain). Nociceptive pain is caused by the ongoing activation of A-δ and C-nociceptors in response to a noxious stimulus. It can be further classified into visceral pain, superficial somatic pain, and deep somatic pain (Perl, 2007; Honore and Jarvis, 2006) . Tissue injury results in the release of pronociceptive mediators that sensitize peripheral nerve terminals that can ultimately lead to increased excitability of spinal cord dorsal horn neurons. As such, injury-induced sensitization of peripheral nerves facilitates a sensitization of the central nervous system.
A multitude of receptors, transmitters, second messenger systems, transcription factors, and other signaling molecules are now appreciated to be involved in pain pathways (Perl, 2007; Honore and Jarvis, 2006) .
The ability of ATP (Figure 1 ), to modulate neural function has been well documented (Burnstock and Williams, 2000; Burnstock, 2007) . Mechanistic understanding of the role for ATP in processing painful sensory information was initially indicated by early demonstrations that ATP was released from sensory nerves (Holton and Holton, 1954; Holton, 1959) and by subsequent data showing that ATP produces fast excitatory action potentials in dorsal root ganglionic (DRG) neurons (Jahr and Jessel, 1983) . While the inhibitory effects of adenosine (ADO) and direct acting ADO receptor agonists on nociceptive neurotransmission and nocifensive behavior have been generally accepted (Sawynok, 2006; McGaraughty and Jarvis, 2006) , the specific (Burnstock, 2007) . It is now known that ATP receptor super-families comprise both G-protein coupled receptors (P1 and P2Y receptors) and ligand gated ion channels (P2X receptors) (North, 2002; Burnstock, 2007) .
P2X receptors function as nonselective cation channels (permeable to Ca 2+ , Na + and K + ) and are expressed on a variety of excitable cells including neurons, glia, and smooth muscle cells (North, 2002; Khakh and North, 2006) . Stimulation of P2X
receptors can also lead to down-stream activation of voltage-operated calcium channels, and Ca 2+ -stimulated tyrosine kinases that in turn activate MAP kinases (ERK1 and ERK2) to modulate transcriptional processing (Khakh and North, 2006) . Extracellular ATP availability arises from a variety of mechanisms including mechanical stimulation, vesicular release with other neurotransmitters (e.g. acetylcholine, norepinephrine, glutamate, GABA, and neuropeptide Y) or by cellular damage (e.g. hypoxia) (Burnstock and Williams, 2000; North, 2002; Burnstock, 2007) . Once released, the extracellular actions of ATP are limited by its rapid degradation by membrane bound and soluble nucleotidases (Burnstock, 2007) . The metabolic degradation of ATP leads to increased extracellular levels of ADP, AMP and ADO, all of which have specific receptor-mediated activities. In the context of nociceptive neurotransmission, activation of P1 receptors by ADO decreases nociception, inflammation, and cellular excitability (McGaraughty and Jarvis, 2006) whereas P2X receptor activation by ATP stimulates cellular excitability, augments the release of excitatory amino acids, initiates nociceptive responses, and can lead to apoptosis (Burnstock and Williams, 2002; Burnstock, 2007 (Moriyama et al., 2003) and propagating calcium-dependent neuronal activity (Burnstock, 2007) .
Historically, a significant limitation in the interpretation of P2 receptor biology has been due to the fact that few, if any, ligands showed meaningful pharmacological selectivity of individual P2 receptor subtypes. Essentially, all of the known P2X receptor agonists have pharmacological activity at multiple P2 receptor subtypes (Jacobson et al., 2002) . Further, traditionally used antagonists such as suramin and PPADS (Figure 2) are generally weak blockers of P2 receptors and have a multitude of other pharmacological actions (Jacobson et al., 2002; Burnstock, 2007) . As discussed below, the discovery of receptor-selective antagonists has helped provide greater clarity as to the specific functional roles of these receptors. receptor agonists (e.g. ATP, α,β-methyleneATP (α,β-meATP), and BzATP; Figure 1 ) are short lasting (1-10 min) and similar in magnitude to that produced in the acute phase of the standard formalin test, a neurogenic inflammatory pain model in rodents (Jarvis et al., 2001) . As has been observed in humans, both the potency and effectiveness of locally administered P2X receptor agonists to elicit nociceptive responses are increased in situations of peripheral inflammation-induced neuronal sensitization (Hamilton et al., 2000; Sawynok, 2007) . Stimulation of spinal P2X receptors may also contribute to nociception as indicated by the ability of intrathecally (i.t.) administered P2X receptor agonists to increase sensitivity to acute and persistent noxious stimuli in rodents (Nakagawa et al., 2007) .
P2X receptor antagonists (e.g. suramin and PPADS, Figure 2 ) have been demonstrated to reduce nociceptive sensitivity in a wide variety of animal models including tail-flick, chemically-induced persistent and inflammatory pain, and neuropathic pain (Inoue, 2006; Sawynok, 2007) . However, their poor selectivity and weak potency has led to conflicting reports of both pronociceptive and antinociceptive effects following P2X receptor blockade (Jarvis, 2003) . Interestingly, P2X agonist-induced receptor desensitization may also lead to reduced pain sensitivity following the initial pronociceptive effect (Inoue, 2006) . TNP-ATP (Figure 2 ) is the most potent P2X 3 receptor antagonist (Jacobson et al., 2003) . TNP-ATP has low nanomolar affinity for blocking P2X 3 receptors, but also has high affinity for P2X 1 receptors and is rapidly degraded in situ (North, 2002) . Thus, in vivo studies of TNP-ATP as a pharmacological tool have been limited to direct intrathecal administration (Jarvis, 2003) or direct administration into a site of peripheral tissue damage (Jarvis et al., 2001; Honore et al., 2002) . and exhibits at least 100-fold less activity across a wide range of kinases, receptors, and ion channels (Gever et al., 2006) . Unlike TNP-ATP, A-317491 is not susceptible to metabolic degradation and shows high systemic bioavailability following subcutaneous administration, but lacks oral bioavailability. RO-3 has lower protein binding (48%) compared to A-317491 (99%) and good CNS penetration (Gever et al., 2006) . Systemic administration of A-317491 effectively reduces nociception in inflammatory and neuropathic pain models . A-317491 also effectively blocked persistent pain in the formalin and acetic-acid induced abdominal constriction tests, but was generally inactive in models of acute noxious (thermal, mechanical, and chemical) stimulation. The less active R-enantiomer of A-317491, A-317334, was inactive in animal pain models . RO-3 has also been reported to reduce nociceptive sensitivity in animal pain models (Gever et al., 2006) . > 500 µM), which inhibit other P2X receptor-related currents in the low µM range (Khakh and North, 2006) . Unlike other P2X receptors, P2X 4 currents evoked by ATP can be potentiated by ivermectin (Khakh and North, 2006) . Co-expression of P2X 4 with P2X 1 (P2X 1/4 ) or P2X 6 (P2X 4/6 ) leads to the expression of cationic currents that are pharmacologically distinguishable from homomeric P2X 4 -mediated currents (North, 2002) . However, it remains to be elucidated whether heteromeric P2X 1/4 and P2X 4/6 receptors form functional channels in native tissues. In a very recent report (Guo et al., 2007) , a functional heteromeric combination of P2X 4 and P2X 7 (P2X 4/7 ) receptors has been described in mouse macrophages.
Recent studies indicate that P2X 4 receptors may play a role in the development of neuropathic and inflammatory pain. P2X 4 mRNA expression has been observed in the dorsal root ganglion (DRG), spinal cord, and several regions of the brain (Kim et al., 2003) . Following spinal nerve injury, P2X 4 receptor protein expression increased in spinal microglia but not in neurons or astrocytes (Inoue, 2006) whereas P2X 4 receptor expression remained unchanged in DRG neurons (Kim et al., 2003 (Inoue, 2006) .
Following peripheral nerve injury, a trans-synaptic shift in anion gradient in spinal lamaina I neurons, due to the down-regulation of the potassium-chloride exporter, KCC2 (Coull et al., 2003) , may transform normally inhibitory anionic synaptic currents to be excitatory, substantially driving up the net excitability of lamina I neurons. This enhanced antagonists will elicit analgesic effects in neuropathic and inflammatory pain states.
P2X 7 Receptors
Homomeric P2X 7 receptors are activated by high concentrations of ATP (>100 µM) (North, 2002) . Prolonged (> 60 sec) agonist activation leads to the formation of large cytolytic pores in the cell membrane (North, 2002; Burnstock, 2007; Di Virgilio, 2006 Surprenant et al., 1996; Burnstock, 2007) . Within the CNS, P2X 7 receptors are localized on microglia and Schwann cells, as well as on astrocytes (North, 2002; Burnstock, 2007) .
ATP acting at P2X 7 receptors serves as an efficient secondary stimulus for the maturation and release of IL-1β from pro-inflammatory cells (Ferrari et al., 2006; Mackenzie et al., 2001; Perregaux and Gabel, 1994) . The activation of P2X receptors results in a rapid but reversible channel opening that is permeable to Ca 2+, Na + , and K + ions (North, 2002) . P2X 7 receptor mediated increases in intracellular K + concentrations leads to the activation of caspase-1 and the rapid maturation and release of the proinflammatory cytokine, IL-1β (DiVirgilio, 2006; Perregaux and Gabel, 1994; Solle et al., 2001; Ferrari et al., 2006) . P2X 7 (-/-) mice show a disruption in cytokine signaling cascades with perturbation of ATP-induced processing of pro-IL-1β in macrophages (Ferrari et al., 2006) . P2X 7 (-/-) mice also show a decreased incidence and severity of arthritis as compared to wild-type control mice in a collagen monoclonal antibodyinduced model of arthritis (Labasi et al., 2002) . Collectively, these data have provided support for the hypothesis that P2X 7 receptor activation may function as a danger signal in the context of tissue trauma and inflammation (Ferrari et al., 2006) .
The finding that disruption of P2X 7 receptors not only altered inflammatory pain, but also reduced pain associated with frank nerve injury (Chessell et al., 2005) , is consistent with the mechanistic role of P2X 7 receptors in modulating IL-1β release and altered pain sensitivity (Wolf et al., 2004) . receptor modulation in reducing nociception in neuropathic pain models.
The robust antinociceptive effects of P2X 7 antagonists in inflammatory pain models does not appear to be secondary to an anti-inflammatory effect since A-740003 was more efficacious in reducing nociception than paw edema (Honore et al., 2006c) . It should be noted, however, that the anti-inflammatory activity of P2X 7 antagonists may be more pronounced in arthritis models as compared to acute (carrageenan) and sub-acute (CFA) inflammatory models since the contribution of IL-1β to ongoing inflammatory processes is more prominent in chronic arthritis (Labasi et al., 2002) .
Using in vivo electrophysiological recording techniques, the antinociceptive action of Studies with P2X 7 receptor-selective ligands provide direct evidence that acute in vivo blockade of P2X 7 receptors significantly reduced nociception in animal models of persistent neuropathic and inflammatory pain (Honore et al., 2006b; McGaraughty et al., 2007) . Collectively, these data combined with growing evidence supporting the role of P2X 7 receptor modulation in pro-inflammatory IL-1 processing (Ferrari et al., 2006) indicates a specific role for P2X 7 receptors in neural-glial cells interactions associated with ongoing pain.
P2Y Receptors
In comparison to several of the P2X receptors, the contributions of the metabotropic P2Y receptors to normal and pathological pain have been less well examined. As with early P2X receptor research, this area of study is currently lacking selective ligands to interrogate the specific contributions of individual P2Y receptor subtypes in pain states. Eight mammalian P2Y receptors have been cloned (P2Y 1, 2, 4, 6, 11, 12, 13, 14 ) that respond in varying degrees to the endogenous ligands ATP, ADP, UTP, and UDP (Figure 1 ) (Burnstock, 2007) . Tissue localization for P2Y receptors is quite diverse. However, the expression of P2Y 1 , P2Y 2 , P2Y 4 , and P2Y 6 mRNA in DRG neurons suggests that these receptors may be involved in peripheral somatosensory transmission (Burnstock, 2007; Moriyama et al., 2003) . In addition to its primary afferent role, there is also some indication that spinal P2Y receptors may modulate pathological nociception (Okada et al., 2002) . Of these four P2Y receptors, 
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Presently, there is limited evidence to suggest that P2Y 4 and P2Y 6 receptors have active roles in nociception. Indeed, it has been shown that P2Y 6 receptors do not influence the activity of primary afferent C-fibers (Stucky et al., 2004) .
P2Y 1 receptor mRNA is upregulated in the lumbar DRG following peripheral axotomy indicating that P2Y 1 receptors may contribute to the heightened somatosensory sensitivity in this pathological state (Xiao et al., 2002) . More specifically, the P2Y 1 receptor has been localized predominantly to small diameter neurons in the DRG and is co-expressed with P2X 3 and transient receptor potential-1 (TRPV1) receptors (Burnstock, 2007; Gerevich et al., 2004; . Activation of P2Y 1 receptors on DRG neurons modulates currents generated through N-type (Ca v 2.2) calcium channels and P2X 3 receptors (Gerevich et al., 2004 (Gerevich et al., , 2005 . Indeed, activation of N-type calcium channels in cultured DRG neurons was inhibited by ATP and even more potently by the P2Y 1,12,13 receptor agonist ADP (Gerevich et al., 2004) . The effects of ATP were blocked by the selective P2Y 1 receptor antagonist, MRS 2179 (Figure 6 ), as well as by PPADS.
Similarly, P2Y 1,12,13 receptor agonists inhibited currents evoked by activation of P2X 3 receptors in cultured DRG neurons from neonatal rats (Gerevich et al., 2005) . Thus, P2Y 1 may serve as an "ATP counterbalance" following mutual activation of P2Y 1 and P2X 3 receptors. However, in human HEK293 cells transfected with P2X 3 receptors, inhibition of P2X 3 currents was reportedly mediated via a P2Y receptor other than P2Y 1 (Gerevich et al., 2007) leaving a putative P2X 3 -P2Y 1 interaction in question.
Nonetheless, the outcome of P2Y 1 -related inhibition on N-type calcium channels or P2X 3 receptors is likely to result in a decreased release of nociceptive transmitters into the spinal cord (Burnstock, 2007) .
Early work with TRPV1-transfected HEK293 cells suggested that the P2Y 1 receptor was responsible for the ATP modulation of TRPV1 responses to heat, capsaicin and protons (Tominaga et al., 2001 ). More recently, this hypothesis has been revised by 
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proposing that the P2Y 2 receptor is the key purinoceptor involved in the modulation of TRPV1 receptor sensitization (Moriyama et al., 2003) . P2Y 2 receptors are expressed on small diameter capsaicin-sensitive DRG neurons (Moriyama et al., 2003; Stucky et al., 2004) . Intraplantar injection of ATP reduced thermal thresholds in both wild type and P2Y 1 deficient mice but not in TRPV1 deficient mice (Moriyama et al., 2003) . These results confirmed the link between ATP-induced thermal hyperalgesia and TRPV1
receptors and also demonstrated that P2Y 1 receptors are not necessary for this interaction. Moreover, the P2Y 2,4 receptor agonist, UTP, potentiated capsaicin-evoked currents in isolated mouse DRG neurons and induced thermal hyperalgesia after intraplantar injection (Moriyama et al., 2003) . The effect on capsaicin currents was blocked by application of the antagonist suramin, which is somewhat more selective for nociception and some aspects of acute inflammatory pain. In contrast, activation of heteromeric P2X 2/3 receptors appears to modulate longer-lasting nociceptive sensitivity associated with nerve injury or chronic inflammation (Jarvis, 2003; Nakagawa et al., 2007) . Additionally, it is now clear that under conditions of persistent nociceptive input, activation of other P2 receptors (e.g. P2X 4 and P2X 7 ) receptors may also serve to maintain nociceptive sensitivity through complex neural-glial cell interactions or via sensitization (via P2Y 2 ) of other nociceptive receptors such as TRPV1 channels.
Of particular note is the recent report of the existence of natively expressed heteromeric P2X 4/7 receptors (Guo et al., 2007; Dubyak, 2007) . This finding provides a potential integrative mechanism of the complex nociceptive roles of both P2X 4 and P2X 7 receptors in chronic pain states. Both receptors share similar sequence homologies, chromosomal localizations, and cellular expression patterns (Dubyak, 2007) . As noted above, they also contribute to similar aspects of ongoing inflammatory and neuropathic pain in experimental models. While the preliminary evidence indicates that the heteromeric P2X 4/7 receptor is sensitive to both P2X 4 and P2X 7 receptor antagonists, further research is needed to clearly differentiate the pharmacological properties of the heteromeric P2X 4/7 receptor from its homomeric partners.
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